Phase IIA clinical trial for ttr amyloidosis successfully completed

SOM Biotech and the Vall d’Hebron Research Institute (VHIR) have completed a Phase IIa Clinical Study with compound SOM0226, a repositioned drug for the treatment of transthyretin amyloidosis. Results show excellent drug efficacy and safety in patients for the treatment of this rare disease. PRESS RELEASE (Spanish) PRESS RELEASE (Catalan) PRESS RELEASE (English)

The release as fetched from its publisher. sombiotech.com ↗